Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD and Safety of Vonafexor in Chronic Hepatitis B
NCT03320616Phase 1Completed
- Sponsor
- ENYO Pharma
- Start
- Feb 2017
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of vonafexor in Chronic Hepatitis B (CHB) (4 arms), sponsored by ENYO Pharma. Primary endpoint: Type and frequencies of adverse events. Started Feb 2017; status: completed.
02
Drugs
vonafexor
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT03320616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03320616.